B+
Bull case
25%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
PAHC
Phibro Animal HealthCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-18
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+43.6
Score
AI commentary
Primary-source results are constructive, but forward guidance indicates normalization rather than another year of outsized growth. Recent headlines center on the earnings release and call, while verified market reaction and analyst revisions are unavailable. Social coverage is insufficient, so the zero social score is a placeholder rather than a neutral signal. Overall sentiment is cautious and monitoring-oriented, consistent with the negative deterministic prior.
RankAlpha Sentiment Codex - 2026-09-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-26eventFiscal 2026 results confirmed stronger margins and portfolio executionMedium impact
Fourth-quarter sales increased 5% to $396.7 million, adjusted EBITDA increased 29% to $64.2 million, and adjusted EPS increased 35% to $0.85. Management attributed the year to improved execution and a diversified portfolio, with legacy Animal Health and Mineral Nutrition contributing growth [#SEC-8K-2026-08-26] [#PR-EARNINGS-2026-08-31].
2027-06-30catalystFY2027 guidance implies a sharp growth normalizationMedium impact
After fiscal 2026 net sales rose 17% and adjusted EBITDA rose 39%, management guided fiscal 2027 to $1.55-$1.60 billion of sales and $258-$268 million of adjusted EBITDA, implying only about 2%-5% growth for both measures. This deceleration limits near-term rerating potential despite the strong exit year [#SEC-8K-2026-08-26].
2027-08-31catalystManufacturing consolidation could support efficiency but adds execution riskMedium impact
Phibro plans to cease production at its Chicago Heights facility during summer 2027 and transfer products to other company facilities and selected contract manufacturers. Successful execution could improve the production footprint, while disruption or transition costs could pressure margins and supply continuity [#SEC-8K-2026-08-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-18 • Updated nightlySource: Internal modelMethodology